Advertisement

July 7, 2021

Scitech Medical’s Embosoft Microspheres Receive CE Mark Approval for Vascular Embolization

July 7, 2021—Scitech Medical, which is headquartered in Brazil, announced that it has received CE Mark approval for the Embosoft microspheres for use in vascular embolization of hypervascular tumors, symptomatic uterine fibroids, and prostatic arteries for the relief of symptoms related to benign prostatic hyperplasia, as well as for hemostatic embolization.

According to the company, Embosoft’s high rate of viscoelasticity and its hydrophilic surface allow a selective distal embolization that is safe and effective.

Embosoft microspheres are composed of the company's Polifit 70 material, which guarantees a well-defined spherical shape and a superior compressibility rate. Because of these characteristics, it is possible to reduce approximately 40% of its size during its delivery and will return to the initial spherical shape without fragmentation or deformation in the target vessel, stated the company.

Advertisement


July 7, 2021

Royal Philips’ Direct to Angio Suite to Improve Stroke Outcomes Evaluated in WE-TRUST Trial

July 7, 2021

Royal Philips Partners With Nico.Lab on Stroke Triage Technology


)